Foldable IOL for glaucoma requires long-term follow-up

Article

Long-term follow-up is necessary in secondary pigmentary glaucoma patients implanted with a foldable IOL in the ciliary sulcus, advises a recent journal paper.

Long-term follow-up is necessary in secondary pigmentary glaucoma patients implanted with a foldable IOL in the ciliary sulcus, advises a recent journal paper.

A team led by Dr Shirley H. L. Chang, Department of Ophthalmology, Chang Gung Memorial Hospital, Chang Gung University, Taiwan, retrospectively reviewed 10 eyes of 10 patients who developed secondary pigmentary glaucoma after cataract operations. Results were based on data collected on cases between 2002 and 2011. Each patient underwent foldable IOL implantation in the ciliary sulcus.

IOP elevation was seen in 2 eyes within the first 2 weeks after cataract surgery and the onset of glaucoma was delayed in the remaining 8 eyes. The average onset time for the 8 eyes was 21.9 ± 17.1 months after the initial cataract operation.

Surgical treatment was administed to six eyes due to large IOP fluctuations and poor IOP control. Of the total eyes studied, only 3 presented with final visual acuities exceeding 20/40.

The visual prognosis for patients with secondary pigmentary glaucoma can be poor and implanting a foldable IOL in the ciliary sulcus could threaten vision. The study group advise that the long-term follow-up of IOP in these patients is required.

To read the abstract please visit BMC Ophthalmology.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.